Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Acute B-Cell Lymphoblastic Leukemia
85%
Adverse Event
31%
Alemtuzumab
23%
Antileukemic Agent
46%
Cell Therapy
42%
Chimeric Antigen Receptor T-Cell
61%
Chimeric Antigen Receptor T-Cell Immunotherapy
51%
Clinical Trial
8%
Cyclophosphamide
14%
Cytokine Release Syndrome
37%
Cytopenia
29%
Diabetes
14%
Diseases
20%
Ethnic Groups
6%
Fludarabine
14%
Graft Versus Host Reaction
14%
Human Study
6%
Imaging Agent
14%
Infection
12%
Infusion
17%
Leukemia
8%
Malignant Neoplasm
14%
Medicine
14%
Minimal Residual Disease
6%
Molecular Imaging
14%
Morphology
6%
Neurotoxicity
8%
Overall Survival
20%
Pediatrics
42%
Progression Free Survival
20%
Progressive Disease
14%
Pulmonary Hemorrhage
8%
Racial Group
6%
Recurrence Free Survival
12%
Reporter Gene
42%
Sepsis
8%
Skin Graft
14%
Stem Cell
42%
Stem Cell Therapy
14%
Stem Cell Transplant
8%
T Cell
42%
Therapy Development
14%
Immunology and Microbiology
Alemtuzumab
17%
Antigen Specificity
11%
B Cell
42%
CD19
42%
Cell Engineering
22%
Cell Line
14%
Chimeric Antigen Receptor
42%
Chimeric Antigen Receptor T-Cell
42%
Chimeric Antigen Receptor T-Cell Therapy
8%
Cotransporter
42%
Cyclophosphamide
8%
Cytokine Release Syndrome
25%
Gene Editing
14%
Gene Technology
14%
Gene Transfer
14%
Genetic Engineering
42%
Graft-Versus-Host Disease
8%
Human Leukocyte Antigen
25%
Human T Regulatory Cell
42%
Immunosuppressive Drug
11%
Interleukin 10
85%
Lentivirus
28%
Overall Survival
8%
positron emission tomographic scan
14%
Progression Free Survival
8%
Regulatory T Cell
100%
Reporter Gene
42%
Single Photon Emission Computed Tomography
14%
Sodium Iodide
42%
Stem Cell Transplant
8%
T Cell
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
85%
Adverse Event
27%
Alemtuzumab
20%
Antileukemic Agent
40%
Chimeric Antigen Receptor
85%
Clinical Trial
7%
Cyclophosphamide
13%
Cytokine Release Syndrome
33%
Cytopenia
26%
Diseases
19%
Fludarabine
13%
Graft Versus Host Reaction
13%
Human Study
6%
Infection
12%
Leukemia
7%
Lung Hemorrhage
7%
Minimal Residual Disease
6%
Neurotoxicity
7%
Overall Survival
19%
Progression Free Survival
19%
Recurrence Free Survival
12%
Sepsis
7%